Visiongain has published a new pharma report Anti-infective Agents Market Report: Anti-viral Infections, Anti-bacterial Infections, Anti-fungal Infections, Hepatitis Virus Infection, HIV Infection, Pneumonia, Aspergillosis, Methicillin-resistant Staphylococcus Aureus (MRSA), Dermatophytosis, Tuberculosis, Respiratory Virus Infection, Sepsis, Hospital Pharmacies, Retail Pharmacies, Online Sales.

The global anti-infective agents market is estimated to have reached $109bn in 2018 and is expected to grow at a CAGR of 4.2% during the forecast period. In 2018, the hospital pharmacy segment dominated the distribution channel of the anti-infective agents market.

This report profiled the selected companies: Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline (GSK), Merck & Co., Novartis AG, Sanofi SA, Pfizer and other companies.

The lead analyst commented that "The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today. There is an increasing focus to identify and treat infectious diseases. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.